Sverak P, et al. - Experts evaluated the efficacy and toxicity of bevacizumab in 17 patients with neurofibromatosis type 2. In order to evaluate radiographic response, researchers conducted volumetric analysis of serial magnetic resonance imaging scans, and evaluated hearing response with serial audiograms. Hearing improvement was recorded in 56% of bevacizumab-treated patients, and tumor volume reduction was noted in 47%. Primary toxicities included hypertension, proteinuria, dysgeusia, and amenorrhea. Overall, results were in line with prior reported series, and there were substantial improvements in patient-reported outcomes that had not been previously described.